Pharmaceuticals

Cocrystal Pharma

Cocrystal Pharma released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 225 K (forecast USD 0), actual EPS USD -0.17 (forecast USD -0.15)

Cocrystal Pharma released FY2025 Annual Earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7821 (forecast USD -0.795)

Cocrystal Pharma released FY2025 Q4 earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1756 (forecast USD -0.175)

Cocrystal Pharma Inc. Begins Phase 1b Study of Oral Antiviral Drug Candidate CDI-988 for Norovirus Infection

Cocrystal Pharma released FY2025 Q3 earnings on November 14, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1864 (forecast USD -0.215)

Cocrystal Pharma released FY2025 9 Months Earnings on November 14 EST, with actual revenue of USD 0 and EPS of USD -0.6145

Cocrystal Pharma Receives NIH Funding to Advance Influenza Inhibitor Program

LeBoyer's Recommended Healthcare Stocks Performance

Cocrystal Pharma Inc. Releases Presentation on Broad-Spectrum Antiviral Drug Development

Cocrystal Pharma released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2019 (forecast USD -0.3)

Cocrystal Pharma released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -0.4281

Cocrystal Pharma Elects Six Board Members and Approves Accounting Firm

HC Wainwright Maintains Buy Rating on Cocrystal Pharma

Cocrystal Pharma Unveils Antiviral Drug Development Projects

Cocrystal Pharma's CC-42344 Shows Strong Antiviral Efficacy Against 2024 H5N1 Avian Influenza Strain

Cocrystal Pharma released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2261 (forecast USD -0.505)

Cocrystal Pharma Inc Reports Q1 Loss of 50 Cents Per Share

Cocrystal Announces CDI-988 Demonstrates Excellent Binding to GII.17 Protease

Cocrystal Pharma released FY2024 annual earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.7204 USD (forecast -1.93 USD)

Cocrystal Pharma released FY2024 Q4 earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.321 USD (forecast -0.53 USD)

Liminatus Pharma

Co-Diagnostics

NewGenIvf

Agape ATP

PicoCELA

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Sunshine Biopharma

Tradr 2X Long RGTI Daily ETF

Wheeler Real Estate

COCP

Earnings Watch

Cocrystal Pharma | 10-Q: FY2026 Q1 Revenue: USD 225 K

ARKG

SBIO

LABU

COCP (Cocrystal Pharma, Inc.) is set to announce its Q1'26 results on May 18, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q1'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (0.15) USD. Learn more details at .Revenue & EPS values are provided in USDQ1'25Q2'25Q3'25Q4'25Q1'26Revenue Reported—————Revenue Estimate—————Revenue SurpriseEPS Reported(0.23)(0.20)(0.19)(0.16) EPS Estimate(0.51)(0.23)(0.21)(0.17)(0.15) EPS Surprise+54.46%+13.04%+11.63%+8.57%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

TradingView

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

COCP Q1'26 Earnings: EPS estimate is (0.15) USD

Sky Quarry, Visionary Education Technology Holdings Group, and Cocrystal Pharma are highlighted as three penny stocks to watch on April 7, based on TipRanks' Penny Stock Screener. These stocks are priced at $5 or below and typically belong to companies with a market cap under $300 million. The Screener helps investors identify stocks using various filters, including Sector, Price Target Upside, and Dollar Volume, with the top three identified based on the highest Dollar Volume as of April 6.

Tip Ranks

Health Care Select Sector SPDR

Visionary

VG Health

iShares US Pharma

iShares Global Healthcare

Sky Quarry

Proshares Ultra Nasdaq Biotech

3 Penny Stocks to Watch Now, 4/7/26

AIXI

In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology stocks and the healthcare sector performing strongly, attracting significant capital inflow. The activity of small-cap stocks and thematic stocks has increased, particularly the rise of Xiao I and Humana, which has drawn market attention. Meanwhile, the decline of 9F stands out, indicating a cautious attitude of capital towards risk appetite. Overall volatility is high, and short-term enthusiasm seems to be accelerating, with market sentiment being relatively active. The stock with the largest movement in the past hour, Xiao I, surged 15.90% in after-hours trading, becoming the market's focus. The rapid inflow of funds has driven its stock price to soar, with short-term sentiment running high, seemingly indicating an optimistic outlook for its future development. 

Strong stocks:
1. Humana: up 12.78%, recent market enthusiasm and capital inflow have made it stand out, attracting investors' attention.
2. Sky Quarry: up 8.00%, against the backdrop of energy transition, the market's optimism about its prospects has driven the stock price up.
3. Unitedhealth: up 7.97%, the strong performance of the healthcare sector has made it a target for capital chasing.
4. Elevance Health: up 7.07%, as market demand for healthcare services increases, its stock price has also risen.
5. Faraday Future Intelligent Electric: up 4.46%, despite facing challenges, the market's expectations for its electric vehicle business remain strong

Price Alert

Xiao I

Humana

Unitedhealth

Elevance Health

Oxbridge Re

Faraday Future Intelligent Electric

Turbo Energy SA

Biodexa Pharmaceuticals

System1

Semilux

Swarmer

U.S. stock movement quick report: Xiao I rose 15.90%, Humana rose 12.78%, 9F fell 11.47%

Cocrystal Pharma, Inc. (COCP) shares are down 11.24% at $1.34 in pre-market trading on Monday, following a 48.04% surge on Thursday. This decline is attributed to profit-taking by traders after the FDA granted Fast Track designation to CDI-988, the first oral antiviral for norovirus. Despite recent volatility, COCP's stock is up 19.84% over the past year, although it remains closer to the lower half of its 52-week range of 86 cents to $2.67, indicating a market still rebuilding confidence after February's low.

Fidelity

Why Cocrystal Pharma Shares Are Cooling Off Monday?

Cocrystal Pharma (NASDAQ:COCP) is facing concerns over its cash burn rate, having $7.0 million in cash and a cash burn of $8.2 million over the past year, indicating a cash runway of about 10 months. Although the company reduced its cash burn by 50% recently, its market capitalization of $21 million means that cash burn represents 39% of its value, raising potential dilution risks for shareholders if new shares are issued. Overall, while the reduction in cash burn is promising, the situation remains risky.

Simplywall

Direxion S&P Biotech Bear 3X

We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

In Thursday's intraday session, several health care stocks experienced significant movements. Profusa (NASDAQ:PFSA) surged 48.6% to $0.86, while Cocrystal Pharma (NASDAQ:COCP) rose 45.1% to $1.48. Bristol-Myers Squibb's Celgene Contingent Value Rights (NYSE:CELGR) increased by 35.32% to $0.12. Conversely, Lipocine (NASDAQ:LPCN) plummeted 78.4% to $2.0, and Inovio Pharmaceuticals (NASDAQ:INO) fell 36.9% to $1.1. Overall, the session saw notable gains and losses among various health care stocks.

benzinga_article

Invesco Nasdaq Biotechnology ETF

Direxion Pharma & Medical Bull 3X

Bristol-Myers Squibb Company

89BIO INC - CONTINGENT VALUE RIGHT

Profusa

Bristol Myers Squibb

12 Health Care Stocks Moving In Thursday's Intraday Session

Cocrystal Pharma, Inc. (COCP) announced that the FDA has granted Fast Track designation to its drug CDI-988 for preventing and treating norovirus infection. The company views this as validation of its structure-based drug discovery technology. Co-CEO Sam Lee stated that CDI-988 shows potential in both preventing and treating the infection. COCP shares are trading at $1.03, up 0.98% on Nasdaq.

rttnews

Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus

Cocrystal Pharma(COCP.US)